Search
BI_Animal_Health.pdf
Idarucizumab_Specific_Reversal_Agent_ dabigatran.pdf
TA Backgrounder - BI R&D Press Conference.pdf
TA Backgrounder - BI R&D Press Conference.pdf
20181130_BI Office Hours-Vienna_flyer_final.pdf
Capabilities infographic FINAL.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
cardiometabolic_flyer_bio_2019.pdf
cns_flyer_bio_2019.pdf
technologies_flyer_bio_2019.pdf
BI-OHNE_Reisecheckliste2018_EN.pdf
2015 09 18 BI in Oncology Backgrounder_6.0_ohne694.pdf
BI 694 backgrounder.pdf
Boehringer_Ingelheim_Biosimilars.pdf
BI Newsletter_Dec_2016_FINAL.pdf
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
meat consumption market trends growth sustainability
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Mexico rabies free dog vaccination campaigns
Mexico: a champion in the fight against rabies. The first country in the world to be declared free from dog-transmitted rabies.
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Sabine Reinig
For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
Rafał Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in our Global Business Service (GBS) Center in Wroclaw, looks back on a bustling beginning with Boehringer Ingelheim – for him and the Center alike.
Combivent® Respimat®
A combination of a short-acting anticholinergic and beta-adrenergic for the management of reversible bronchospasms associated with obstructive airway diseases in patients requiring more than one bronchodilator.